Avacta

Expanding the reach of highly potent cancer therapies with the pre|CISION® platform.

[Avacta @avacta]

Avacta provides a business update ahead of today’s Annual General Meeting of Shareholders, reviewing progress across the portfolio in the first half of 2026 and outlining upcoming milestones. #AVCT https://t.co/9MRKfHT4AE

[Avacta @avacta]

In the 3rd Episode of Avacta Academy, our CEO Chris Coughlin and CSO Francis Wilson speak to the CMC team to explain the nuts and bolts of how a drug moves from the lab to being a medicine, and break down the GMP drug manufacturing process. https://t.co/bnCD6r8dzQ #AVCT

[Avacta @avacta]

In this interview with Ventures Accelerated Life Science, Avacta CEO @coughlin582 shares how Avacta is redefining precision oncology with its tumor-targeted delivery platform, and why this matters for patients, clinicians, and partners. https://t.co/XwKZyOpOPN #AVCT

[Avacta @avacta]

This week we were in London for Venture Road UK 2026, joining the life sciences community to share the progress of our pre|CISION® platform. #AVCT

[Avacta @avacta]

Avacta is pleased to announce that it has raised gross proceeds of approximately £9 million from institutional investors and existing shareholders. https://t.co/3ihy8vVfuK #AVCT

[Avacta @avacta]

In this video presentation, Avacta CEO Christina Coughlin reviews the new faridoxorubicin program data. https://t.co/nN63I5Cxzf #AVCT

[Avacta @avacta]

Download a copy of the poster at https://t.co/J3V1slVeZ7 #AVCT

[Avacta @avacta]

Avacta today released updated Phase 1a/1b and pharmacokinetics, safety, toxicity and preliminary efficacy data with faridoxorubicin at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. https://t.co/yQ7kjJpSbP #AVCT

[Avacta @avacta]

Posting of Annual Report and Notice of AGM. https://t.co/Vs3HmVJhgD #AVCT

[Avacta @avacta]

Avacta today announces that Richard Hughes, one of Avacta’s non-executive Directors, will become non-executive Chairman of Avacta following the Annual General Meeting (AGM) on June 22, 2026. https://t.co/25k4YieSX7 #AVCT

[Avacta @avacta]

Avacta today published its unaudited preliminary results for the 12 months ended December 31, 2025. https://t.co/5N6g9tfpS6 #AVCT

[Avacta @avacta]

We’re pleased to share the recordings from our Science Day. The presentations explore comparative analyses of pre|CISION® payload delivery with AVA6103 vs approved ADCs, alongside updated in vivo studies of the AVA6207 dual payload delivery system. https://t.co/oV0amuV74Q #AVCT

[Avacta @avacta]

Avacta will announce its unaudited preliminary results for the year ended December 31, 2025 on May 19, 2026. https://t.co/Wm9PtbfHxv #AVCT

[Avacta @avacta]

For those who were unable to attend in person, the event was professionally recorded and the video will be made available on the Avacta website in due course. #AVCT

[Avacta @avacta]

Thank you to everyone who attended today's Science Day. The whole team really enjoyed being able to present the exciting progress being made and speak to many of you in person. We are so grateful for your continued support! #AVCT

[Avacta @avacta]

Avacta will today present two new developments at its Science Day 2026 event. Comparative analyses of AVA6103 compared with now two approved Antibody-Drug Conjugates (ADCs). Also, updated in vivo studies of the dual payload delivery program, AVA6207. https://t.co/73ah4tj1bE #AVCT

[Avacta @avacta]

Salivary gland cancer, a rare subset of head and neck cancers, remains an area of significant unmet need. Through our pre|CISION® platform, we are committed to advancing new options for these patients. To everyone whose advocacy makes this research possible, thank you. #AVCT

[Avacta @avacta]

As Head and Neck Cancer Awareness Month draws to a close, we recognize the patients, families, and advocates whose courage and persistence drive progress in these complex diseases. #AVCT #HeadAndNeckCancerAwareness #SalivaryGlandCancer #HopeWithoutCompromise #Oncology #preCISION

[Avacta @avacta]

For those unable to join in person, a recording will be made available on our website once edited. #AVCT

[Avacta @avacta]

We're looking forward to welcoming attendees on May 6 to the Royal Society of Chemistry, London, for presentations on our scientific achievements and the road ahead for our tumor-activated oncology platform, followed by a reception. #AVCT